The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma.
- Author:
Sanjay de MEL
1
;
Yunxin CHEN
2
;
Sathish Kumar GOPALAKRISHNAN
2
;
Melissa OOI
1
;
Constance TEO
3
;
Daryl TAN
4
;
Min Li Claire TEO
2
;
Allison Cy TSO
5
;
Lian King LEE
5
;
Chandramouli NAGARAJAN
2
;
Yeow Tee GOH
2
;
Wee Joo CHNG
1
Author Information
- Publication Type:Journal Article
- Keywords: Singapore; evidence-based; guideline; multiple myeloma
- MeSH: Aged; Antibodies, Monoclonal; chemistry; Biomarkers, Tumor; Female; Humans; Male; Medical Oncology; standards; Middle Aged; Multiple Myeloma; diagnosis; therapy; Practice Guidelines as Topic; Proteasome Endopeptidase Complex; Quality of Life; Risk; Singapore; Societies, Medical; Stem Cell Transplantation; Transplantation Conditioning
- From:Singapore medical journal 2017;58(2):55-71
- CountrySingapore
- Language:English
- Abstract: Multiple myeloma (MM) is an incurable plasma cell neoplasm with an incidence of 100 patients per year in Singapore. Major advances have been made in the diagnosis, risk stratification and treatment of MM in the recent past. The reclassification of a subset of patients with smouldering MM, based on high-risk biomarkers, and the development of the revised international staging system are among the key new developments in diagnosis and staging. The use of novel agent-based treatment has resulted in significant improvements in the survival and quality of life of many patients with MM. Determining the optimal use of proteasome inhibitors, immunomodulators and, more recently, monoclonal antibodies is an area of ongoing investigation. In this guideline, we aim to provide an overview of the management of MM, incorporating the latest developments in diagnosis and treatment.
